K Pharma,Inc.
Tokyo Stock ExchangeTotal Valuation
K Pharma,Inc. carries a market capitalization of 8.28B, placing it among publicly traded companies globally. Its enterprise value stands at 6.14B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 8.28B |
| Enterprise Value | 6.14B |
Share Statistics
K Pharma,Inc. currently has 11.60M shares outstanding.
| Shares Outstanding | 11.60M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
| PE Ratio | N/A |
| PS Ratio | N/A |
| PB Ratio | -27.05 |
| P/TBV Ratio | 3.30 |
| P/FCF Ratio | N/A |
| P/OCF Ratio | N/A |
Financial Position
K Pharma,Inc. maintains a current ratio of 34.93, meaning it holds 34.9x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 34.93 |
| Quick Ratio | 33.81 |
| Debt / Equity | N/A |
| Debt / EBITDA | N/A |
| Interest Coverage | N/A |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -27.16 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Taxes
| Income Tax | -57.85M |
| Effective Tax Rate | N/A |
Stock Price Statistics
K Pharma,Inc.'s stock has gained approximately 1.56919% over the past 52 weeks. The 50-day moving average sits at 699.42, while the 200-day moving average is 704.81.
| Beta (5Y) | N/A |
| 52-Week Price Change | 1.56919% |
| 50-Day Moving Average | 699.42 |
| 200-Day Moving Average | 704.81 |
| Average Volume (20 Days) | N/A |
Income Statement
EBITDA reached -708.54M, while operating income came in at -708.54M.
| Revenue | N/A |
| Gross Profit | N/A |
| Operating Income | -708.54M |
| Pretax Income | -738.80M |
| Net Income | -680.95M |
| EBITDA | -708.54M |
| EBIT | -708.54M |
| Earnings Per Share (EPS) | -58.68 |
Balance Sheet
Total book value stands at -326.50M, with working capital of 2.70B providing operational flexibility.
| Cash & Cash Equivalents | 2.69B |
| Total Debt | N/A |
| Net Debt | -2.69B |
| Equity (Book Value) | -326.50M |
| Book Value Per Share | -28.14 |
| Working Capital | 2.70B |
Scores
K Pharma,Inc. posts an Altman Z-Score of 47.85, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 47.85 |